- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 436307, 7 pages
Interleukin-17: A Promoter in Colorectal Cancer Progression
Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, Key Laboratory of Molecular Biology in Medical Sciences, China National Ministry of Education), Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang 310009, China
Received 30 August 2013; Revised 23 October 2013; Accepted 30 October 2013
Academic Editor: Rosalinda Sorrentino
Copyright © 2013 Dang Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013.
- A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008.
- S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, no. 6, pp. 883–899, 2010.
- C. Ferrone and G. Dranoff, “Dual roles for immunity in gastrointestinal cancers,” Journal of Clinical Oncology, vol. 28, no. 26, pp. 4045–4051, 2010.
- L. Klampfer, “Cytokines, inflammation and colon cancer,” Current Cancer Drug Targets, vol. 11, no. 4, pp. 451–464, 2011.
- J. Terzić, S. Grivennikov, E. Karin, and M. Karin, “Inflammation and colon cancer,” Gastroenterology, vol. 138, no. 6, pp. 2101.e5–2114.e5, 2010.
- E. Rouvier, M. F. Luciani, M. G. Mattei, F. Denizot, and P. Golstein, “CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene,” Journal of Immunology, vol. 150, no. 12, pp. 5445–5456, 1993.
- J. K. Kolls and A. Lindén, “Interleukin-17 family members and inflammation,” Immunity, vol. 21, no. 4, pp. 467–476, 2004.
- Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, “Functional specialization of interleukin-17 family members,” Immunity, vol. 34, no. 2, pp. 149–162, 2011.
- C. Y. Kao, Y. Chen, P. Thai et al., “IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways,” Journal of Immunology, vol. 173, no. 5, pp. 3482–3491, 2004.
- G. Matsuzaki and M. Umemura, “Interleukin-17 as an effector molecule of innate and acquired immunity against infections,” Microbiology and Immunology, vol. 51, no. 12, pp. 1139–1147, 2007.
- L. E. Mays, S. Ammon-Treiber, B. Mothes, et al., “Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism,” Journal of Clinical Investigation, vol. 123, no. 3, pp. 1216–1228, 2013.
- A. Hot and P. Miossec, “Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes,” Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 727–732, 2011.
- R. A. Shilling and D. S. Wilkes, “Role of Th17 cells and IL-17 in lung transplant rejection,” Seminars in Immunopathology, vol. 33, no. 2, pp. 129–134, 2011.
- Q. Zhang, S. Liu, D. Ge et al., “Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models,” Cancer Research, vol. 72, no. 10, pp. 2589–2599, 2012.
- G. Murugaiyan and B. Saha, “Protumor vs antitumor functions of IL-17,” Journal of Immunology, vol. 183, no. 7, pp. 4169–4175, 2009.
- W. J. Chae, T. F. Gibson, D. Zelterman, L. Hao, O. Henegariu, and A. L. M. Bothwell, “Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 12, pp. 5540–5544, 2010.
- D. J. Cua and C. M. Tato, “Innate IL-17-producing cells: the sentinels of the immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 479–489, 2010.
- M. Huber, A. Brüstle, K. Reinhard et al., “IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 52, pp. 20846–20851, 2008.
- X. O. Yang, A. D. Panopoulos, R. Nurieva et al., “STAT3 regulates cytokine-mediated generation of inflammatory helper T cells,” The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9358–9363, 2007.
- K. Hirahara, K. Ghoreschi, A. Laurence, X. Yang, Y. Kanno, and J. J. O'Shea, “Signal transduction pathways and transcriptional regulation in Th17 cell differentiation,” Cytokine and Growth Factor Reviews, vol. 21, no. 6, pp. 425–434, 2010.
- E. Segura, M. Touzot, A. Bohineust et al., “Human inflammatory dendritic cells induce Th17 cell differentiation,” Immunity, vol. 38, no. 2, pp. 336–348, 2013.
- K. Hirahara, K. Ghoreschi, X. P. Yang et al., “Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1,” Immunity, vol. 36, no. 6, pp. 1017–1030, 2012.
- H. Raifer, A. J. Mahiny, N. Bollig et al., “Unlike αβ T cells, γδ T cells, LTi cells and NKT cells do not require IRF4 for the production of IL-17A and IL-22,” European Journal of Immunology, vol. 42, no. 12, pp. 3189–3201, 2012.
- B. Afzali, P. J. Mitchell, F. C. Edozie et al., “CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner,” European Journal of Immunology, vol. 43, no. 8, pp. 2043–2054, 2013.
- M. Huber, S. Heink, A. Pagenstecher, et al., “IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis,” Journal of Clinical Investigation, vol. 123, no. 1, pp. 247–260, 2013.
- N. Takahashi, I. Vanlaere, R. de Rycke et al., “IL-17 produced by Paneth cells drives TNF-induced shock,” Journal of Experimental Medicine, vol. 205, no. 8, pp. 1755–1761, 2008.
- Y. Miyahara, K. Odunsi, W. Chen, G. Peng, J. Matsuzaki, and R. Wang, “Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 40, pp. 15505–15510, 2008.
- E. Tartour, F. Fossiez, I. Joyeux et al., “Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice,” Cancer Research, vol. 59, no. 15, pp. 3698–3704, 1999.
- L. Benevides, C. R. Cardoso, D. G. Tiezzi, H. R. Marana, J. M. Andrade, and J. S. Silva, “Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor,” European Journal of Immunology, vol. 43, no. 6, pp. 1518–1528, 2013.
- D. M. Kuang, C. Peng, Q. Zhao, Y. Wu, M. Chen, and L. Zheng, “Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells,” Hepatology, vol. 51, no. 1, pp. 154–164, 2010.
- L. Lv, K. Pan, X. D. Li et al., “The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma,” PLoS ONE, vol. 6, no. 3, Article ID e18219, 2011.
- Y. Zhuang, L. S. Peng, Y. L. Zhao et al., “CD8+ T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer,” Gastroenterology, vol. 143, no. 4, pp. 951.e8–962.e8, 2012.
- S. Le Gouvello, S. Bastuji-Garin, N. Aloulou et al., “High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas,” Gut, vol. 57, no. 6, pp. 772–779, 2008.
- J. S. Nam, M. Terabe, M. J. Kang et al., “Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17,” Cancer Research, vol. 68, no. 10, pp. 3915–3923, 2008.
- M. Numasaki, J. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003.
- M. Numasaki, M. Watanabe, T. Suzuki et al., “IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis,” Journal of Immunology, vol. 175, no. 9, pp. 6177–6189, 2005.
- F. M. Gu, Q. L. Li, Q. Gao et al., “IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma,” Molecular Cancer, vol. 10, article 150, 2011.
- L. Wang, T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu, “IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1457–1464, 2009.
- N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009.
- F. Benchetrit, A. Ciree, V. Vives et al., “Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism,” Blood, vol. 99, no. 6, pp. 2114–2121, 2002.
- N. Hirahara, Y. Nio, S. Sasaki et al., “Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice,” Oncology, vol. 61, no. 1, pp. 79–89, 2001.
- N. Hirahara, Y. Nio, S. Sasaki et al., “Reduced invasiveness and metastasis of Chinese hamster ovary cells transfected with human interleukin-17 gene,” Anticancer Research, vol. 20, no. 5, pp. 3137–3142, 2000.
- K. Oshiro, H. Kohama, M. Umemura et al., “Interleukin-17A is involved in enhancement of tumor progression in murine intestine,” Immunobiology, vol. 217, no. 1, pp. 54–60, 2012.
- D. S. Straus, “TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells,” Molecular Cancer, vol. 12, article 78, 2013.
- Y. S. Hyun, D. S. Han, A. R. Lee, C. S. Eun, J. Youn, and H. Kim, “Role of IL-17A in the development of colitis-associated cancer,” Carcinogenesis, vol. 33, no. 4, pp. 931–936, 2012.
- S. Wu, K. J. Rhee, E. Albesiano et al., “A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses,” Nature Medicine, vol. 15, no. 9, pp. 1016–1022, 2009.
- S. I. Grivennikov, K. Wang, D. Mucida, et al., “Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth,” Nature, vol. 491, no. 7423, pp. 254–258, 2012.
- C. Ma and X. Dong, “Colorectal cancer-derived Foxp3+IL-17+ T cells suppress tumour-specific CD8+ T cells,” Scandinavian Journal of Immunology, vol. 74, no. 1, pp. 47–51, 2011.
- A. S. Chung, X. Wu, G. Zhuang et al., “An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy,” Nature Medicine, vol. 19, no. 9, pp. 1114–1123, 2013.
- S. Yang, B. Wang, C. Guan et al., “Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer,” Journal of Leukocyte Biology, vol. 89, no. 1, pp. 85–91, 2010.
- J. Liu, Y. Duan, X. Cheng et al., “IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma,” Biochemical and Biophysical Research Communications, vol. 407, no. 2, pp. 348–354, 2011.
- I. Kryczek, S. Wei, W. Szeliga, L. Vatan, and W. Zou, “Endogenous IL-17 contributes to reduced tumor growth and metastasis,” Blood, vol. 114, no. 2, pp. 357–359, 2009.
- T. Kinugasa, T. Sakaguchi, X. Gu, and H. Reinecker, “Claudins regulate the intestinal barrier in response to immune mediators,” Gastroenterology, vol. 118, no. 6, pp. 1001–1011, 2000.
- S. F. Ngiow, M. J. Smyth, and M. W. L. Teng, “Does IL-17 suppress tumor growth?” Blood, vol. 115, no. 12, pp. 2554–2555, 2010.
- G. Radosavljevic, B. Ljujic, I. Jovanovic et al., “Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma,” Neoplasma, vol. 57, no. 2, pp. 135–144, 2010.
- I. Sobhani, J. Tap, F. Roudot-Thoraval et al., “Microbial dysbiosis in colorectal cancer (CRC) patients,” PLoS ONE, vol. 6, no. 1, Article ID e16393, 2011.
- G. Cui, A. Yuan, R. Goll, and J. Florholmen, “IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence,” Scandinavian Journal of Gastroenterology, vol. 47, no. 11, pp. 1304–1312, 2012.
- D. Wågsäter, S. Löfgren, A. Hugander, and J. Dimberg, “Expression of interleukin-17 in human colorectal cancer,” Anticancer Research, vol. 26, no. 6, pp. 4213–4216, 2006.
- M. Tosolini, A. Kirilovsky, B. Mlecnik et al., “Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer,” Cancer Research, vol. 71, no. 4, pp. 1263–1271, 2011.
- I. Kryczek, K. Wu, E. Zhao et al., “IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer,” Journal of Immunology, vol. 186, no. 7, pp. 4388–4395, 2011.